Cardiovascular Outcomes and the Use of Oral Antidiabetic Drugs: A Review of Current Evidence from Observational Studies

Elnaem M.H.\textsuperscript{a,b}, Mohd Azam F\textsuperscript{c}, Akkawi ME\textsuperscript{a,b}
\textsuperscript{a}Department of Pharmacy Practice, Kulliyyah of Pharmacy, International Islamic University Malaysia
\textsuperscript{b}Quality Use of Medicines Research Group, Kulliyyah of Pharmacy, International Islamic University Malaysia

ABSTRACT

Type 2 diabetes mellitus (T2DM) is a major global disease burden that affects millions of people worldwide. The disease is well known to predispose patients to a wide range of macro- and microvascular complications. Cardiovascular complications are common macrovascular consequences among patients with T2DM. The primary goal of T2DM management is to achieve proper glycaemic control that helps to avoid or delay the incidence of disease complications. T2DM management involves the utilisation of oral antidiabetic medications and injectables, including insulin. Hence, we conducted this work to discuss and summarise the cardiovascular outcomes associated with the oral antidiabetic pharmacotherapy prescribed for patients with T2DM. The agents involved were metformin, sulfonylurea, dipeptidyl peptidase-4 inhibitors, thiazolidinediones, alpha-glucosidase inhibitors, and sodium-glucose cotransporter-2 inhibitors. We decided to focus on the findings reported from observational studies published between 2009 to 2019 to provide an updated and more realistic insight on these cardiovascular outcomes associated with the oral antidiabetic drugs in the usual clinical practice.

KEYWORDS: cardiovascular outcomes, oral antidiabetic drugs, oral hypoglycaemic agents.

INTRODUCTION

Type 2 diabetes mellitus (T2DM) is a significant global disease burden that affects millions of people worldwide. By the year 2035, it is estimated about 592 million people around the world will have T2DM, which is predominantly associated with insulin secretory defects based on the incidence of insulin resistance related to inflammation, stress, overweight, and obesity.\textsuperscript{1} The disease is well known to predispose patients to a wide range of complications due to alterations of normal physiological functions, leading to macro- and microvascular changes.\textsuperscript{2}

Cardiovascular (CV) complications are common macrovascular consequences among patients with T2DM due to their increased susceptibility to metabolic risk factors for atherosclerotic cardiovascular disease.\textsuperscript{3} It has been reported that people with diabetes are at two to four times higher mortality rate due to cardiovascular events compared to healthy individuals.\textsuperscript{2} Moreover, there is an increment for the mortality trend of patients with T2DM attributed to cardiovascular complications, which might inflict a growing burden on the healthcare system and warrant more efforts towards reducing diabetes-related cardiovascular disease.\textsuperscript{4} Although the use of lipid-lowering therapy (LLT) for cardiovascular disease (CVD) prevention among patients with T2DM has been well established, there are reported challenges on the effectiveness of LLT use among patients with T2DM in both, hospital and primary care settings.\textsuperscript{5,6}

Moreover, achieving proper glycaemic control, as the primary goal of T2DM management, helps to avoid or delay the incidence of disease complications apart from controlling other cardiometabolic risks.\textsuperscript{7} T2DM management involves the utilisation of oral antidiabetic medications and injectables, including insulin. The role of glycaemic control in managing cardiovascular outcomes is complex because specific oral antidiabetic agents show benefits; meanwhile,
others carry relatively more risks and hence should be individualised. Therefore, we conducted this work to discuss and summarise the cardiovascular outcomes associated with the oral antidiabetic pharmacotherapy prescribed for patients with T2DM. The involved agents were metformin, sulfonylurea (S.U.), dipeptidyl peptidase-4 inhibitors (DPP4i), thiazolidinediones (TZD), alpha-glucosidase inhibitors, and sodium-glucose cotransporter-2 inhibitors (SGLT2i). We decided to focus on the findings reported from observational studies published between 2009 to 2019 to provide an updated and more realistic insight on these cardiovascular outcomes associated with oral antidiabetic drugs (ADD) in the usual clinical practice.

**METHODODOLOGY**

A literature search of the published observational studies that reported cardiovascular outcomes associated with the use of ADD was undertaken in December 2019. The searches were limited to the last ten years (2009-2019) to provide a review of the most recently published evidence. Three scientific databases, Google Scholar, Science Direct, and PubMed, were searched using predefined terms. Two reviewers screened all the initially identified studies for its relevancy, English language, and article type (original research involving adult T2DM patients). Observational studies reported negative or positive effects of oral antidiabetic drugs (ADD) on the CV outcomes among T2DM patients were included. Review articles, meta-analysis studies, case reports, book chapters, and conference proceedings were excluded. A study-specific extraction form was developed and used to retrieve the information from the included studies. The overview chart describing the selection of the articles is illustrated in Figure 1. Moreover, we have formulated the following key research questions to guide our search and decision on the final included studies.

1. What are the commonly reported CV outcomes associated with the use of different oral ADD in observational studies?
2. What are the differences in the reported CV outcomes between various oral ADD either as monotherapy or combination therapy in observational studies?

**RESULTS**

Of the initially identified 397 studies, 22 studies were finally included in this review. Concerning the countries in which the research was conducted, a total of nine studies were conducted in Asian countries (Taiwan and South Korea); meanwhile, seven studies were carried out in European countries (Denmark, France, U.K). Also, five studies were undertaken in the U.S. Only one study included data from both the U.S. and European countries (Sweden, Denmark, Norway, and the U.K). The findings of the included studies show that conventional ADDs, like metformin and S.U., were present in almost more than half of the comparisons with other ADD monotherapies. A relatively fewer number of studies were reported for SGLT2i, where only three studies investigated its associated CV outcomes. Furthermore, the findings showed that the majority of the studies (18/22) included ADD monotherapies, whereas combination therapies were reported in only four out of the 22 included studies. The design, setting, objectives, and main results of the included studies are summarised in table 1.

**DISCUSSION**

Overall, there were differences in the number of observational studies that reported CV outcomes for different ADDs. For example, many studies were available for both metformin and S.U., followed by DDP4i. Meanwhile, relatively few studies were available for newer agents such as SGLT2i. In addition, there were documented differences in the degree of CV benefits and risks associated with ADD monotherapy, particularly in comparative studies. The variations in these reported CV outcomes imply a consequently relative preference of particular agents based on the existing comorbidities and intercurrent illness. Metformin is a widely prescribed first-line treatment for the majority of T2DM patients. According to Eurich et al. (2013), the use of metformin for diabetic patients with H.F. either alone or in combination with S.U. lesser morbidity and mortality in comparison to S.U. monotherapy. Many studies have highlighted the relative CV benefits of metformin compared to S.U.
metformin resulted in better CV outcomes in high-risk patients that is further strengthened with the long-term beneficial impact of metformin related to its antiatherosclerosis properties beyond the glucose-lowering effect. On the other hand, it has been observed that males have a higher risk of metformin-associated myocardial infarction than females implying sex-drug interactions in describing the CV safety of oral ADD. The trend showed an increased risk of CV death and ischemic stroke for the S.U. therapy compared to metformin monotherapy. Also, the data that the patients on S.U. more prone to have in-hospital mortality when comparing to the patients who did not receive S.U. treatment.

Furthermore, adding or switching S.U. to metformin associated with decreased risk of MI, severe hypoglycemia, and all-cause mortality compared to metformin monotherapy. In a French study, it has been highlighted that glibenclamide was associated with a higher risk for in-hospital mortality compared to glimepiride and glimepiride. Nevertheless, gliclazide treatment was associated with a declined rate of primary endpoint events of major microvascular and macrovascular complications. Moreover, it is worthy to note that there are few differences between S.U. agents related to their safety profile, such as cardiac adverse events. A Danish nationwide study has highlighted that gliclazide lower CV and mortality risk compared to other S.U. agents, even glimepiride, which was previously hypothesised to reduce MI preconditioning. The differences in CV safety shown by different S.U.s denote the importance of the careful selection of S.U. agent, particularly in diabetic patients with coronary artery diseases. As a combination therapy, S.U. added to metformin conferred a higher risk of hospital hospitalisation compared to the DPP4i added to metformin. Also, as monotherapies, DPP4i a safer ADD to be offered to diabetic patients with H.F. compared to glimepiride.
Table 1: Summary of the main characteristics and retrieved information from the included selected studies (N=22)

<table>
<thead>
<tr>
<th>Author &amp; Country</th>
<th>Study design &amp; population</th>
<th>Objectives</th>
<th>Key findings</th>
<th>Conclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tzoulaki et al. 2009 17 (U.K.)</td>
<td>Retrospective cohort study included 91,521 patients.</td>
<td>To explore the association between ADD and H.F. and all-cause mortality.</td>
<td>• S.U. showed a higher risk of all-cause mortality. Second-generation agents showed significantly 18% to 30% higher H.F. risk compared to metformin. • Pioglitazone reduced the risk of all-cause mortality significantly by 31% to 39% compared to metformin.</td>
<td>Compared to metformin, S.U. had an increased risk for H.F., while pioglitazone had a lower risk for all-cause mortality.</td>
</tr>
<tr>
<td>Zeller et al. 2010 18 (France)</td>
<td>Retrospective Cohort study included 1,310 diabetics who had prior MI admission.</td>
<td>To investigate the link between receiving S.U. before admission and the incidence of MI compared to insulin and other ADD.</td>
<td>• S.U. users had a lower mortality risk (3.9%, ( P=0.014 )), compared to those on insulin (9.4%), or other ADD (6.4%). • Pancreatic-cell specific agents, e.g., gliclazide and glimepiride, showed significantly lower in-hospital mortality (2.7%, ( P=0.019 )) compared to glibenclamide (7.5%).</td>
<td>The S.U. use before the acute MI episode showed no additional risk when compared to insulin or other ADDs.</td>
</tr>
<tr>
<td>Gallagher et al. 2011 19 (U.K.)</td>
<td>Cohort study included 206,940 T2DM adult patients.</td>
<td>To assess the CV risk and mortality associated with the use of TZD.</td>
<td>• Rosiglitazone showed higher mortality risk (aRR 1.20; 95% CI 1.08-1.34) and HF-related hospitalization (aRR of 1.73; 95% CI 1.19-2.51) compared to pioglitazone.</td>
<td>Lower CV risks were reported for pioglitazone in comparison to rosiglitazone.</td>
</tr>
<tr>
<td>Schramm et al. 2011 9 (Denmark)</td>
<td>Nationwide cohort study involved 107,806 T2DM patients.</td>
<td>To compare the CVD and mortality risk between insulin secretagogues (I.S.s) and metformin.</td>
<td>• Unlike all I.S.s, gliclazide and repaglinide showed no statistically significant different CVD and mortality risk compared to metformin.</td>
<td>Gliclazide and repaglinide showed lower CVD and mortality risk compared to other I.S.s.</td>
</tr>
<tr>
<td>Roumie et al. 2012 20 (USA)</td>
<td>Retrospective cohort study included 253,690 veterans newly initiated on S.U. or metformin monotherapy.</td>
<td>To compare the impact of S.U. and metformin on CV outcomes.</td>
<td>• The incidence of adverse CV outcomes was higher in S.U. users compared to metformin users (aHR: 1.21, CI, 1.13-1.30).</td>
<td>Initial treatment with S.U. was associated with higher risks of CV adverse events compared to metformin.</td>
</tr>
<tr>
<td>Chen et al. 2014 10 (Taiwan)</td>
<td>Nationwide cohort study included 644,792 patients without pre-existing CVD who have been initiated on acarbose.</td>
<td>To evaluate the possible CV outcomes of acarbose in T2DM patients.</td>
<td>• The aHR for CV adverse events was 1.14, 0.64, and 0.41 for the duration of consuming acarbose &lt; 12 months, 12 to 24 months, and &gt; 24 months, respectively. • After the primary CVD, uninterrupted use of acarbose exposed neutral effect within the first 12 months, followed by a positive effect when it was continued for &gt; 12 months.</td>
<td>Acarbose showed a temporary escalation in the CVD incidence in the first 12 months, followed by a substantial decline of CVD in persistent users.</td>
</tr>
<tr>
<td>Mogensen et al. 2015 21 (Denmark)</td>
<td>Retrospective nation-wide study involved patients on S.U. plus insulin (n=11,081), or metformin plus insulin (n=16,910).</td>
<td>To compare the CV outcomes between S.U. and metformin combinations with insulin.</td>
<td>• The combination of S.U. and insulin was associated with an increased risk of all-cause mortality and CV death compared to the combination of metformin and insulin.</td>
<td>Metformin plus insulin was associated with less adverse CV outcomes compared to S.U. and insulin.</td>
</tr>
<tr>
<td>Year</td>
<td>Study TYPE</td>
<td>Country</td>
<td>Study Design</td>
<td>Study Objective</td>
</tr>
<tr>
<td>------</td>
<td>------------</td>
<td>---------</td>
<td>--------------</td>
<td>-----------------</td>
</tr>
<tr>
<td>2015</td>
<td>Cohort study</td>
<td>Taiwan</td>
<td>Nationwide cohort study involving patients received acarbose (n=17,366) or metformin (n=230,023)</td>
<td>To compare the CV outcomes associated with the initiation of acarbose and metformin.</td>
</tr>
<tr>
<td>2016</td>
<td>Cohort study</td>
<td>South Korea</td>
<td>A retrospective cohort study involved patients received sitagliptin (n=1620) or metformin (n=3240)</td>
<td>To investigate the CV safety of sitagliptin compared to metformin.</td>
</tr>
<tr>
<td>2016</td>
<td>Cohort study</td>
<td>U.K.</td>
<td>Open cohort study involved 469,668 T2DM patients who were prescribed with at least one ADD, particularly DPP4i and TZD.</td>
<td>To evaluate the relationship between the risk of CVD, H.F., and all-cause mortality and the use of ADD.</td>
</tr>
<tr>
<td>2016</td>
<td>Retrospective study</td>
<td>Taiwan</td>
<td>A nationwide longitudinal study involved T2DM patients (n=123,050) who had received recently ADD.</td>
<td>To compare CV safety associated with DPP4i compared to other ADDs.</td>
</tr>
<tr>
<td>2016</td>
<td>Retrospective study</td>
<td>USA</td>
<td>A retrospective cohort analysis included 13.5 million T2DM patients on oral ADD with a previous hospitalization linked to their diabetes.</td>
<td>To compare between S.U. and other ADDs in terms of the risk for diabetes-related hospitalization readmission.</td>
</tr>
<tr>
<td>2016</td>
<td>Case-control study</td>
<td>Taiwan</td>
<td>Nested case-control study included 8936 patients who received at least one oral ADD and diagnosed with aortic aneurysm.</td>
<td>To explore the association between oral ADD and the risk for development aortic aneurysm.</td>
</tr>
<tr>
<td>2017</td>
<td>Retrospective study</td>
<td>USA</td>
<td>A retrospective cohort study among adult T2DM patients who received either SGLT2i (n=4899) or DPP4i (n=9798).</td>
<td>To evaluate the relative risk of H.F. hospitalization of DPP4i compared to SGLT2i.</td>
</tr>
</tbody>
</table>

* SGLT2i: Sodium-glucose cotransporter 2 inhibitors
* TZD: Thiazolidinediones
* DPP4i: Dipeptidyl peptidase-4 inhibitors
* S.U.: Sulfonylureas
* CVD: Cardiovascular disease
<table>
<thead>
<tr>
<th>Study</th>
<th>Study Design</th>
<th>Study Population</th>
<th>Aim</th>
<th>Key Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chin et al. 2017</td>
<td>Retrospective cohort study</td>
<td>T2DM patients who received glimepiride (n=13,447) or DPP4i (n=6504)</td>
<td>To assess the CV safety of DPP4i compared to glimepiride.</td>
<td>There was no significant escalation of the total CV events with the use of DPP4i compared to glimepiride (aHR, 0.87; 95% CI, 0.75-1.01). DPP4i use showed a decreased risk of hospitalization for H.F. compared with the use of glimepiride (aHR, 0.58; 95% CI, 0.37-0.89).</td>
</tr>
<tr>
<td>Kim et al. 2018</td>
<td>A nationwide retrospective study of 59,479 patients on SGLT2i and matched with those on DPP4i</td>
<td>To compare the H.F. protective effect of SGLT2i and DPP4i.</td>
<td>SGLT2i showed a lower risk of H.F. hospitalization (H.F.: 0.66, 95% CI: 0.58-0.75) compared to DPP4i. The SGLT2i effect was observed 30 days in new users with underlying CVD and late in patients without underlying CVD.</td>
<td></td>
</tr>
<tr>
<td>Raghavan et al. 2018</td>
<td>Cohort study involving 5352 veterans patients with well-controlled T2DM and CAD</td>
<td>To compare the link between S.U. vs. non-SU and mortality risk.</td>
<td>S.U. users have experienced unadjusted higher mortality compared to non-SU (11.9% vs. 5.2%). In a fully adjusted model, there was no significant difference between the two groups.</td>
<td></td>
</tr>
<tr>
<td>Chan et al. 2018</td>
<td>Retrospective nationwide cohort study involving 26,742 patients who received second-line ADD.</td>
<td>To assess the CV risk of adding second-line ADD to metformin.</td>
<td>TZD (aHR: 0.66, p = 0.004) and alpha-glucosidase inhibitors (aHR: 0.74, p = 0.01) have significantly lower risk of adverse CV outcomes compared to SU.</td>
<td></td>
</tr>
<tr>
<td>Antonios Douros et al. 2018</td>
<td>A population-based cohort study included 77,138 patients on metformin, from them 25,699 experienced addition or switching to S.U.</td>
<td>To investigate the impact of adding or switching to S.U. compared to metformin monotherapy on the CV safety.</td>
<td>Compared to metformin, S.U. was associated with 26%, 28% increase in the risk of MI, and all-cause mortality, respectively. Switching to S.U. was found to confer higher MI risk compared to adding it with metformin therapy.</td>
<td></td>
</tr>
<tr>
<td>Cavender et al. 2018</td>
<td>Prospective cohort study involving 306,156 T2DM patients who were newly started on ADD.</td>
<td>To investigate the association between the initiation of SGLT2i and CV events compared to other ADD.</td>
<td>Compared with other ADD, initiation of SGLT2i reduced the risk of H.F. in patients with (H.R.: 0.72; 95% CI: 0.63-0.82) and without CVD (H.R.: 0.61; 95% CI:0.48-0.78), respectively.</td>
<td></td>
</tr>
</tbody>
</table>

DPP4i did not elevate CV risk and could be a safer option for H.F. patients compared to glimepiride. SGLT2i has a better cardioprotective effect compared with DPP4i, particularly in patients with underlying CVD. S.U. confer higher CV risk compared to non-SU, e.g., metformin among patients with well-controlled T2DM and CAD. The add-on therapy using alpha-glucosidase inhibitors or TZD was linked to a lower CV risk compared to S.U. S.U. use conferred higher CV risk compared to metformin monotherapy. Adding S.U. to metformin had a lower risk than switching to S.U. monotherapy. Initiating SGLT2i treatment in patients with or without CVD demonstrated a lesser incidence of H.F. compared to other ADD. |
In a retrospective Korean cohort study, the findings suggested that Asian diabetic patients could have higher benefits, such as achieving average baseline blood glucose in patients with lower body mass index, by using DPP4i relative to other ethnic groups. Furthermore, the data from Taiwan’s National Health Insurance Research Database indicated that DPP4i had lower risks for cardiovascular complications as compared to those not receiving DPP4i, except for metformin. Besides, DPP4i was associated with a decreased risk of hospitalisation for CVDs among patients with a history of visits for CVDs compared to glimepiride.

In addition, data from meta-analysis indicated a decreasing risk of MACE hospitalisation or death among saxagliptin users. Compared to other oral ADDs except TZD, DPP4i reported a decrease in all-cause mortality and heart failure by 18% and 14%, respectively. The data on DPP4i highlighted the effect of ethnicity on the net benefits of oral ADD. It also offered some important insights into the variation in CV outcomes by modifying one ADD in combination therapy.

Supported with growing evidence, SGLT2i showed a better CV safety profile compared to DPP4i in terms of the risk of H.F. hospitalization, especially in elderly patients with diabetic complications. The relative preference of SGLT2i over DPP4i for cardiac protective action was underpinned among patients with underlying CVD compared to those with no underlying CVD. Moreover, in a multinational study, initiation of SGLT2i has been associated with an overall lower incidence of H.F. in patients with or without underlying CVD compared to other ADDs. Similarly, another assessment involved data from six countries supported the CV outcomes of SGLT2i over other ADDs in terms of reducing H.F. hospitalization and death. Interestingly, consistent with the evidence supporting the favourable impact of SGLT2i on CV outcomes, empagliflozin, and canagliflozin demonstrated lower risks of H.F. Hospitalization compared to placebo. Fortunately, the benefits of SGLT2i in lowering the risk of admission with H.F. and death were consistent across the SGLT2i class but with a descending ranking order of relative preference as empagliflozin, dapagliflozin, and canagliflozin.

Acarbose, which is indicated to normalize postprandial hyperglycemia, could reduce the oxidative stress and, therefore, prevent endothelial dysfunction that could lead to cardiovascular
A nationwide study from Taiwan established that acarbose treatment either as monotherapy or in combination with the other ADDs in patients with T2DM without pre-existing CVD showed a temporary escalation in the incidence of cardiovascular complication in the first 12 months followed by the substantial declination of cardiovascular disease in the persistent use of acarbose population. According to the Acarbose Cardiovascular Evaluation trial, acarbose users did not get any direct CV protective effects compared to placebo, and the only difference reported was in the less frequency of developing diabetes among current users. Therefore, it is thought that the prolonged use of acarbose might indirectly reduce CV events by slowing or preventing hyperglycemia in people with CHD. Also, the add-on therapy by using acarbose with metformin is preferable compared to sulfonylureas due to their lower risk of cardiovascular adverse effects, although this effect was not significant in patients associated with a history of heart failure. On the contrary, another nationwide cohort study based on the Taiwan National Health Insurance Database a higher risk of hospitalization for ischemic stroke, heart failure, and myocardial infarction in diabetic patients who use initial therapy receiving acarbose compared to metformin initiators. Furthermore, acarbose did not reduce the risk of MACE in Chinese patients with CHD and impaired glucose tolerance but had an impact on reducing the incidence of diabetes compared to placebo.

TZD, such as pioglitazone and rosiglitazone, are approved as highly selective peroxisome proliferator-activated receptor γ agonists, which could manage inflammatory modulators and at once reduce the risk of coronary atherosclerosis. Pioglitazone was correlated with a 31% to 39% lesser risk of all-cause mortality in comparison to metformin. Additionally, pioglitazone had an advantage over rosiglitazone by increasing the high-density lipoprotein concentration and lowering the triglycerides concentrations, and therefore, it could reduce the progression rate on the thickness of carotid intima-media and indirectly decrease the risk of coronary atherosclerosis. Furthermore, lower risks for death and heart failure were established for pioglitazone. This result indicated that rosiglitazone has less favourable safety profile compared to pioglitazone. On the other hand, the data from the Korean Diabetes Association showed that TZD as an add-on medication to metformin has no significant reduction of the risk of H.F. hospitalization in diabetic patients compared to metformin plus S.U. Hence, concerning this issue, TZD might not be a preferred ADD for patients at high risk of H.F. hospitalization. Furthermore, in a retrospective cohort study conducted in the UK to compare the CV risk of ADD added to metformin therapy, TZD showed a significantly lower CVD risk and death compared to S.U. Whereas DPP4i showed a trend of a statistically insignificant lower risk. So, in patients with CVD and diabetes, a careful selection of the ADD should consider the underlying CVD disease and patient characteristics. In the absence of heart failure, both metformin and SGLT2i were consistent in demonstrating CV safety benefits. Further addition of TZD, DPP4i, then lastly S.U. agents could be considered for combination therapies. In the case of concomitant heart failure, there is evidence supporting the relative preference of SGLT2i agents to be included in the diabetes pharmacotherapy plan.

CONCLUSION

Referring to the highlighted variations in the degree of CV protection between the various ADDs, few issues merit consideration by the prescriber, such as the effectiveness of the use of ADD between different genders and patient groups. Also, the comparison of CV safety of agents of the same class of drugs and the special precautions needed for individual agents should be considered. These issues may affect weighing the risks and benefits for each agent, and hence recommendations should be individualised. Considering that the use of ADD combination therapies is increasingly seen in the practice as supported by the guidelines, so more supporting evidence concerning the CV outcomes of ADD combination therapy is still needed.

ACKNOWLEDGMENT

This work was supported by the Research Management Center of the International Islamic University Malaysia under grant number RIGS17-122-0697.
REFERENCES


